Net income
-10.2 million USD
2025-07-01 – 2026-06-30
Fundies. English
SHUTTLE PHARMACEUTICALS HOLDINGS, INC.
EDGAR31 filing records in this dataset, filed from 2022-06-03 to 2026-10-22. Reported financial figures are available; chart coverage varies by period.
- Cash and cash equivalents
- 90.2 thousand USD Source
Exact value
90238 USD
- Long-term debt including current maturities
- 91 thousand USD Source
Exact value
91021 USD
- Shares outstanding
- 1 million shares Source
Exact value
1001165 shares
Reported share-count change
-6.50% · -69.6 thousand shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Operating cash flow
-6.58 million USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
- Operating cash flow: -8508633 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -5881979 USD · 2025-01-01 – 2025-06-30 Source
- Operating cash flow: -9481645 USD · 2025-01-01 – 2025-12-31 Source
- Operating cash flow: -8508633 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: -2417309 USD · 2026-01-01 – 2026-03-31 Source
- Operating cash flow: -2984949 USD · 2026-01-01 – 2026-06-30 Source
- Operating cash flow: -2417309 USD · 2026-01-01 – 2026-03-31 Source
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-10-22.
Financial data available through: 2025-12-31.
Coverage by financial measure
- revenue: No compatible figures in this window
- Operating income: 6 of 11 periods available· newest 2025-12-31
- Net income: 6 of 11 periods available· newest 2025-12-31
- Operating cash flow: 6 of 11 periods available· newest 2025-12-31
- Capital expenditure: 2 of 11 periods available· newest 2023-12-31
- Total assets: 6 of 11 periods available· newest 2025-12-31
- Total liabilities: 6 of 11 periods available· newest 2025-12-31
- Current assets: 6 of 11 periods available· newest 2025-12-31
- Current liabilities: 6 of 11 periods available· newest 2025-12-31
- Cash and cash equivalents: 5 of 11 periods available· newest 2025-12-31
- Long-term debt including current maturities: 1 of 11 periods available· newest 2021-12-31
- Shares outstanding: 6 of 11 periods available· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
−USD 2.56 millionPrior period
−USD 9.14 million
–
Current period
−USD 11.7 million
–
Exact inputs and evidence
-11700000 − -9144797 = -2555203 USD
-9144797 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-11700000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 2.15 millionPrior period
−USD 7.33 million
–
Current period
−USD 9.48 million
–
Exact inputs and evidence
-9481645 − -7327230 = -2154415 USD
-7327230 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-9481645 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue, Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Not enough comparable data to show this history.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2020 2020-01-01 – 2020-12-31 | −USD 805,732 Exact valueExact value: -805732 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 26,831 Exact valueExact value: -26831 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 10,818 Exact valueExact value: 10818 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 37,649 Calculation and evidence-26831 − 10818 USD Exact free cash flow: -37649 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2021 2021-01-01 – 2021-12-31 | −USD 1.15 million Exact valueExact value: -1152134 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 300,336 Exact valueExact value: -300336 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2022 2022-01-01 – 2022-12-31 | −USD 5 million Exact valueExact value: -4996069 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 2.67 million Exact valueExact value: -2666411 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2023 2023-01-01 – 2023-12-31 | −USD 6.59 million Exact valueExact value: -6592723 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 5.58 million Exact valueExact value: -5581147 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 19,046 Exact valueExact value: 19046 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 5.6 million Calculation and evidence-5581147 − 19046 USD Exact free cash flow: -5600193 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2024 2024-01-01 – 2024-12-31 | −USD 9.14 million Exact valueExact value: -9144797 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 7.33 million Exact valueExact value: -7327230 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2025-01-01 – 2025-12-31 | −USD 11.7 million Exact valueExact value: -11700000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 9.48 million Exact valueExact value: -9481645 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
31 filings · 888 latest values · 888 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001757499, 1757499, SHPH, edgar:1757499
Also known as SHUTTLE PHARMACEUTICALS HOLDINGS, INC., Shuttle Pharmaceuticals Holdings, Inc.